WO2019098628A1 - 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 - Google Patents
결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 Download PDFInfo
- Publication number
- WO2019098628A1 WO2019098628A1 PCT/KR2018/013761 KR2018013761W WO2019098628A1 WO 2019098628 A1 WO2019098628 A1 WO 2019098628A1 KR 2018013761 W KR2018013761 W KR 2018013761W WO 2019098628 A1 WO2019098628 A1 WO 2019098628A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seizure
- epilepsy
- absence
- formula
- group
- Prior art date
Links
- 206010010904 Convulsion Diseases 0.000 title claims abstract description 127
- -1 carbamate compound Chemical class 0.000 title claims abstract description 30
- 208000003554 absence epilepsy Diseases 0.000 title claims abstract description 20
- 208000028311 absence seizure Diseases 0.000 title claims abstract description 19
- 206010034759 Petit mal epilepsy Diseases 0.000 title claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000012453 solvate Substances 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- 206010015037 epilepsy Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 230000002068 genetic effect Effects 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 7
- 201000008189 Juvenile absence epilepsy Diseases 0.000 claims description 7
- 210000000744 eyelid Anatomy 0.000 claims description 7
- 208000016132 Epilepsy with myoclonic absences Diseases 0.000 claims description 6
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 6
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims description 6
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 claims description 6
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims description 6
- 125000006731 (C1-C8) thioalkoxy group Chemical group 0.000 claims description 5
- 208000003078 Generalized Epilepsy Diseases 0.000 claims description 5
- 208000022120 Jeavons syndrome Diseases 0.000 claims description 5
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 4
- 206010003628 Atonic seizures Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 238000000537 electroencephalography Methods 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 230000001186 cumulative effect Effects 0.000 description 14
- 229940102566 valproate Drugs 0.000 description 14
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000001647 drug administration Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 7
- 206010061334 Partial seizures Diseases 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 3
- 229960002767 ethosuximide Drugs 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
- 229960001848 lamotrigine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960001918 tiagabine Drugs 0.000 description 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 208000020131 Acid-base disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000001913 Childhood absence epilepsy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010071081 Idiopathic generalised epilepsy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- LLDGTQQQDRJOGX-MRVPVSSYSA-N NC(OC[C@@H](C[n]1nncn1)c1ccccc1Cl)=O Chemical compound NC(OC[C@@H](C[n]1nncn1)c1ccccc1Cl)=O LLDGTQQQDRJOGX-MRVPVSSYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010034057 Partial complex seizures Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- GSHUZVSNIBLGMR-UHFFFAOYSA-N calcium;1,1-dioxo-1,2-benzothiazol-3-one Chemical compound [Ca].C1=CC=C2C(=O)NS(=O)(=O)C2=C1 GSHUZVSNIBLGMR-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
Definitions
- the present invention relates to the use of a carbamate compound of the formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, for the prophylaxis, amelioration or treatment of epilepsy which is indicative of absence seizure or seizures It is about:
- R 1 , R 2 , A 1 and A 2 are as defined herein.
- seizures All of the symptoms caused by temporary and irregular abnormal excitations of neurons are called seizures, and they are called seizures and have special causes such as electrolyte imbalance, acid-base disorder, uremia, alcohol withdrawal, severe sleep deprivation And the like.
- the disease group in which chronic seizures appear even if there is no abnormality in the body that can cause seizures is called anaplastic. It is known that continuous medication is needed when more than 2 seizures occur.
- the epileptic seizures are classified into partial seizures and systemic seizures.
- the partial seizures are classified into two types: epileptic seizures and nerve cell seizures originating from a part of the cerebral cortex (cortex) , And a systemic seizure refers to a seizure that begins in a wide area of both hemispheres of the cerebrum.
- the types of generalized seizures include generalized tense seizures, seizure seizures (seizures), seizures, and seizures without tension.
- the types of partial seizures include simple partial seizures, complex seizures, and partial seizures. (Source: Korean Institute of Craniophysiology).
- seizures are sudden seizures that stop sudden behavior, dizziness or dizziness, lasting 5-10 seconds. Occasionally you can observe a slight tremor around the eyes or in the mouth. There is a characteristic that appears well when you breathe (Source: Korean Institute of Craniophysiology).
- EEG electroencephalography
- SWD spike-and-wave discharges
- the types of epilepsy that have symptomatic seizures include child absence epilepsy, epilepsy with myoclonic absence, juvenile absence epilepsy, juvenile absence epilepsy, Seizures (juvenile myoclonic epilepsy).
- the shoe can be divided into a typical absence and an atypical absence.
- Orthopedic seizures usually end within 2 to 10 seconds and rarely last longer than 30 seconds. Therefore, the patient himself, as well as others, sometimes do not know whether he or she has a seizure. After a seizure, he or she returns to an action or situation just before the seizure without being aware of the seizure.
- Atypical presentation may manifest as loss of consciousness, increased eye gaze, blinking of eyelids, re-appetizing, chewing, or fingering, and the frequency may decrease before and after puberty, There is a tendency.
- Valproic acid or ethosuximide, and lamotrigine may be used but is less effective (Glauser et al. (2010) "Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy ", New England Journal of Medicine, 362 (9): 790-9).
- Other examples include carbamazepine, vigabatrin, tiagabine, oxcarbazepine, phenytoin, phenobarbital, gabapentin, pregabalin, (NICE Guidelines) Retrieved 3 November 2014; Knake et al., (August 8, 1999).
- anticonvulsant medications such as pregabalin, can aggravate seizure outbreaks. &Quot; Tiagabine-induced absence status in idiopathic generalized epilepsy ", European Journal of Epilepsy 8 (5): 314-317).
- Carpalamide dibenzazepine drugs are used to treat partial seizures, but this class of drugs is known to aggravate common seizures, especially seizures.
- the present invention seeks to provide a method for preventing, alleviating or treating epilepsy which is indicative of an absence seizure or a seizure.
- the present invention also provides a use of a carbamate compound of the following formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof for use in the prevention, alleviation or treatment of epileptic seizures showing seizures or seizures It is to:
- R 1 , R 2 , A 1 and A 2 are as defined herein.
- the present invention provides a pharmaceutical composition for the prevention, alleviation or treatment of epileptic seizures exhibiting a seizure onset or seizure seizure comprising a therapeutically effective amount of a carbamate compound of the formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof to provide:
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 8 alkyl, halo C 1 -C 8 alkyl, C 1 -C 8 thioalkoxy and C 1 -C 8 alkoxy,
- One of A 1 and A 2 is CH and the other is N.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a carbamate compound of formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and further comprising one or more pharmaceutically acceptable carriers, Or preventing epileptic seizures, such as seizures or seizures.
- the present invention also relates to the use of a carbamate compound of formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in a therapeutically effective amount to treat a subject suffering from epileptic seizures, Prevention, alleviation, or cure.
- the present invention also provides a use of the carbamate compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, for the prevention, alleviation or treatment of epileptic seizures, such as seizures or seizures.
- R 1 and R 2 in the general formula (1) are each independently selected from the group consisting of hydrogen, halogen and C 1 -C 8 alkyl.
- a halo-C 1 -C 8 alkyl is a perfluoroalkyl.
- the carbamate compound of Formula 1 is carbamic acid (R) -1- (2-chlorophenyl) -2-tetrazol-2-yl) ethyl ester of Formula 2:
- the carbamate compounds of Formulas (1) and (2) above can be prepared by using known compounds or compounds which can be easily prepared therefrom, as long as those skilled in the art are familiar with the synthesis of the compounds.
- the process for preparing the compound of formula 1 is described in detail in WO 2006/112685 A1, WO 2010/150946 A1 and WO 2011/046380 A2, which are incorporated herein by reference.
- the compound of the formula (1) can be synthesized chemically by the method described in the above document, but it is merely a suggestion of one exemplary method, and the order of the unit operation and the like can be selectively changed as necessary, Is not intended to limit.
- the carbamate compound of Formula 1 may be used for preventing, alleviating or treating epileptic seizures showing seizures or seizures.
- the above-mentioned shoe shoes can be divided into a largely large regular absence and an atypical absence.
- Orthopedic seizures usually end within 2 to 10 seconds and rarely last longer than 30 seconds. Therefore, the patient himself, as well as others, sometimes do not know whether he or she has a seizure. After a seizure, he or she returns to an action or situation just before the seizure without being aware of the seizure.
- Atypical presentation may manifest as loss of consciousness, increased eye gaze, blinking of eyelids, re-appetizing, chewing, or fingering, and the frequency may decrease before and after puberty, There is a tendency.
- epilepsy which indicates a seizure event, includes child absence epilepsy, epilepsy with myoclonic absence, juvenile absence epilepsy, , Juvenile myoclonic epilepsy, Jeavons syndrome (eyelid myoclonia with absences), genetic generalized epilepsy with phantom absences with epileptic seizures, , And Lennox-Gastaut syndrome. ≪ / RTI >
- the shoe may be a small or atypical absence. It may also include all seizures that have spike-and-wave discharges (SWD) as a feature of EEG.
- SWD spike-and-wave discharges
- the carbamate compound of formula (1) can be applied to epileptic seizures that show a seizure or seizure seizure through the ability to inhibit spike-and-wave discharges (SWD).
- SWD spike-and-wave discharges
- the efficacy of the carbamate compound of formula (I) for epileptic seizures can be confirmed by using a known model.
- GAERS genetic absence epilepsy rat from France
- SWD spike-and-wave discharges
- the neuropsychiatric epilepsy is a model used to test the efficacy of seizure treatment agents (Depaulis et al. ; 260: 159-74).
- SWD is characterized by cerebral cortical EEG recordings, which lasts for about 17 to 25 seconds at one time and about 45 to 60 times per hour. These SWDs are also associated with halting activity, a behavioral feature of seizure seizures. Similar to patients, it is known that SWD in GAERS model rats is also inhibited by valproate, ethosuximide, etc., and many drugs have no inhibitory effect or some drugs exacerbate SWD (Dedeurwaerdere et al.), Fluctuating and constant valproate administration in rats with genetic and acquired epilepsy. Seizure.
- the dosage of the carbamate compound of formula (I) for the prevention, amelioration or treatment of the disease will usually vary depending on the severity of the disease, the body weight of the subject being treated and the metabolic status.
- a " therapeutically effective amount " for an individual patient means an amount sufficient to achieve the above pharmacological effect, i. E., A therapeutic effect.
- the therapeutically effective amount of the compound of formula (I) may be in the range of 50 to 500 mg, 50 to 400 mg, 50 to 300 mg, 100 to 400 mg, 100 to 300 mg, 50 to 200 mg, or 100 to 400 mg, 200 mg.
- the compounds of the present invention may be administered by any conventional method used for administration of therapeutic agents, such as oral, parenteral, intravenous, intramuscular, subcutaneous or rectal administration.
- a pharmaceutical or pharmaceutical composition according to one embodiment of the present invention comprises a therapeutically effective amount of a compound selected from the group consisting of a carbamate compound of the invention, a pharmaceutically acceptable salt, solvate, hydrate thereof and combinations thereof can do.
- the pharmaceutically acceptable salts of the carbamate compounds of Formula 1 include, for example, acetate, benzenesulfonate, benzoate, bitartrate, calcium acetate, camsylate, carbonate, citrate, ede But are not limited to, tartrate, eddylate, esterylate, esterylate, esterylate, ethylate, fumarate, glucosate, gluconate, glutamate, glycoloylarsanylate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, But are not limited to, sodium carbonate, sodium carbonate, sodium carbonate, sodium carbonate, sodium carbonate, sodium carbonate, sodium carbonate, sodium carbonate, sodium carbonate, sodium carbonate, Pateoate (embonate), pantothenate, phosphate / diphosphate, polygalactous europaea It.
- Salicylates stearates, subacetates, succinates or hemi-succinates, sulphates or hemi-sulphates, tannates, tartrates, oxalates or hemi-tartrates, theoclates, triethiodides , Benzenetine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, ammonium, tetramethylammonium, calcium, lithium, magnesium, potassium, sodium and zinc.
- the pharmaceutical or pharmaceutical composition according to one embodiment of the present invention may be administered orally or parenterally.
- parenteral administration intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration , Intravaginal administration, intrapulmonary administration, rectal administration, and the like.
- the pharmaceutical composition according to one embodiment may be formulated to be nasal, or to be coated against, or protected from degradation from, the active agent.
- the composition may be administered by any device capable of transferring the active agent to the target cell.
- the route of administration may vary depending upon the general conditions and age of the subject to be treated, the nature of the treatment conditions, and the active ingredient selected
- the appropriate dosage of the pharmaceutical or pharmaceutical composition according to one embodiment of the present invention may be appropriately determined depending on the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, Factors, and the ordinarily skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis.
- the pharmaceutical composition according to one embodiment may be administered in one or more doses, for example, one to four times per day.
- the pharmaceutical composition according to one embodiment comprises the compound of Formula 1 in a concentration of from 50 to 500 mg, 50 to 400 mg, 50 to 300 mg, 100 to 400 mg, 100 to 300 mg, 50 to 200 mg, Or 100 to 200 mg.
- the pharmaceutical composition or the pharmaceutical composition according to one embodiment of the present invention may be prepared by using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art Or may be prepared in unit dosage form by injection or by intrusion into a multi-dose container.
- the formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
- the pharmaceutical composition may be administered in the form of suppositories, sprays, ointments, creams, gels, inhalants or skin patches.
- the pharmaceutical composition may also be prepared for mammalian administration, more preferably for human administration.
- Pharmaceutically acceptable carriers may be solid or liquid and may be in the form of pharmaceutical preparations such as excipients, antioxidants, buffers, bacteriostats, dispersants, adsorbents, surfactants, binders, preservatives, disintegrants, sweeteners, flavors, lubricants, release modifiers, Stabilizers, suspending agents, and lubricants.
- pharmaceutically acceptable carriers may be selected from saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and mixtures thereof.
- suitable fillers include sugars (such as dextrose, sucrose, maltose and lactose), starches (such as corn starch), sugar alcohols (e.g., mannitol, sorbitol, maltitol, erythritol, Starch hydrolyzates (e.g., dextrin and maltodextrin), celluloses or cellulose derivatives (such as microcrystalline cellulose), or mixtures thereof, but are not limited thereto.
- sugars such as dextrose, sucrose, maltose and lactose
- starches such as corn starch
- sugar alcohols e.g., mannitol, sorbitol, maltitol, erythritol, Starch hydrolyzates (e.g., dextrin and maltodextrin), celluloses or cellulose derivatives (such as microcrystalline cellulose), or mixtures thereof, but are not limited thereto.
- sugar alcohols e.g.
- suitable binders include povidone, copovidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, gum, sucrose, starch or Mixtures of these may be used, but are not limited thereto.
- suitable preservatives include, but are not limited to, benzoic acid, sodium benzoate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, gallate, hydroxybenzoate, EDTA, But is not limited thereto.
- suitable disintegrants include starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starch, microcrystalline cellulose, or mixtures thereof But is not limited thereto.
- suitable sweeteners may be sucralose, saccharin, sodium or potassium or calcium saccharin, acesulfame potassium or sodium cyclamate, mannitol, fructose, sucrose, maltose or mixtures thereof It is not limited.
- suitable glidants include, but are not limited to, silica, colloidal silicon dioxide, talc, and the like.
- suitable lubricants include, but are not limited to, long chain fatty acids and salts thereof, such as magnesium stearate and stearic acid, talc, glyceride wax, or mixtures thereof.
- preventing As used herein, the terms “ preventing ", “ preventing “, and “ prevention” are intended to reduce the likelihood of or susceptibility to disease.
- alleviate refers to alleviating all or part of the disease and /
- treat refers to the elimination of all or part of the disease and / or its attendant symptoms.
- subject refers to an animal, preferably a mammal (e.g., primates (e.g., a person), cow, sheep, goat, horse, dog , A cat, a rabbit, a mouse, a mouse, etc.), and most preferably a human.
- a mammal e.g., primates (e.g., a person), cow, sheep, goat, horse, dog , A cat, a rabbit, a mouse, a mouse, etc.
- therapeutically effective amount as used herein is intended to be sought by a researcher, veterinarian, physician or other clinician, and includes biological or medicinal products in a tissue system, animal or human, including alleviating the symptoms of the disease or disorder Quot; means the amount of active compound or pharmaceutical agent that elicits the response.
- composition encompasses any product that results, directly or indirectly, from a product comprising a specified amount of a particular ingredient and a specified amount of a particular ingredient combination.
- the medicament and the pharmaceutical composition according to the present invention can effectively treat and prevent epilepsy, which shows a seizure onset and a seizure onset.
- FIG. 1 shows electroencephalography (EEG) measurement results observed under the baseline conditions of the GAERS model used in the embodiment. It can be seen that spontaneous SWD is occurring.
- FIG. 2 shows the results of EEG analysis of the effect of valproate used as a positive control group on the frequency of occurrence of SWD in the GAERS model.
- 150 mg / kg and 200 mg / kg was analyzed.
- the number of SWD episodes in the baseline period of 20 minutes before drug administration and the total number of SWD episodes during 80 minutes from 10 minutes to 90 minutes after drug administration were shown.
- FIG. 3 shows the effect of the test compound on the number of SWD occurrences in the GAERS model as a result of analyzing the EEG by analyzing EEG, and the effect was evaluated at 4, 10, 20 and 30 mg / kg four doses.
- the number of SWD occurrences during the baseline period of 20 minutes before the administration of the test compound and the number of SWD occurrences for a total of 80 minutes from 10 minutes to 90 minutes after administration of the test compound were shown.
- FIG. 4 shows the number of times of occurrence of SWD for a total of 60 minutes from 10 minutes to 70 minutes after administration of the drug or the test compound. The difference in effect between the vehicle-administered group, the test compound administered group and the valproate-administered group can be confirmed.
- FIG. 5 is a graph showing the effect of valproate used as a positive control group on the cumulative duration time of SWD occurring in the GAERS model by EEG analysis. As a result, it was confirmed that the efficacy at 150 mg / kg and 200 mg / Respectively. The cumulative duration of SWD for the baseline period of 20 minutes before drug administration and the cumulative duration of SWD for every 20 minutes from 10 to 90 minutes after drug administration were shown.
- FIG. 6 shows the effect of the test compound on the cumulative duration of the SWD in the GAERS model as a result of EEG analysis, and the efficacy was evaluated at the dose of 4, 5, 10, 20 and 30 mg / kg.
- the cumulative duration of SWD at the baseline period of 20 minutes before the administration of the test compound and the cumulative duration of the SWD at 20 minutes from 10 to 90 minutes after administration of the test compound were shown.
- FIG. 7 shows the cumulative duration of SWD in units of 20 minutes in a total of 60 minutes from 10 minutes to 70 minutes after administration of the drug or the test compound.
- the difference in the effect between the group administered with vehicle, the group administered with test compound, and the group administered with valproate have.
- GAERS Genetic absence epileptic rat from Strabourg
- GAERS has typical behavior, electrophysiological, and pharmacological characteristics of absence seizure, and for about 20 years GAERS has been used as a disease model for seizures (Depaulis et al., The genetic absence of epilepsy rat from France as a model to decipher the neuronal and network mechanisms of generalized idiopathic epilepsies J Neurosci Methods. 2016 Feb 15; 260: 159-74).
- EEG electrodes were implanted in 12 GAERS at 3 months of age. Stereotaxic transplantation was performed under anesthesia with isoflurane (2% oxygen concentration). Ophthalmic gel was used to prevent drying of the cornea. After cutting the hair of the area to be incised, it was disinfected with povidone, and after the incision was made, four holes were drilled using a drill to the frontal cortex of the hemispheres of the open skull and the parietal cortex of the paris. A monopolar electrode was placed in these holes and connected to a female connector fixed to the skull for EEG recording. The incision was then sutured. After surgery, buprenorphine was injected subcutaneously at a dose of 0.1 mg / kg, followed by removal of the anesthetic and observation until recovery of consciousness. Thereafter, they were kept in a cage for recovery for one week.
- Test compounds and positive control drugs were prepared immediately before administration.
- the test compound was dissolved in 30% (volume / volume) of PEG 300 (81164-14) using the carbamic acid (R) -1- (2- chlorophenyl) , Sigma-Aldrich), and positive control valproate (P4543, Sigma-Aldrich) was dissolved in 0.9% sterile saline (Cooper, France). 30% PEG 300 was used for vehicle administration for negative control.
- the test was conducted in a cross-over manner with a minimum interval of 71 hours between each administration for wash-out of the drug.
- the following conditions were given:
- Test compound 20 mg / kg
- Test compound 30 mg / kg
- EEG recording 10 GAERS were placed in a recording chamber and connected to a wire for EEG recording. After an hour of habituation, EEG records were recorded for freely moving animals. Baseline was recorded for 20 minutes before drug administration, 90 minutes after drug administration, and SystemPlus Evolution (Micromed) was used. During the recording, the animals maintained a quiet wakefulness state.
- SWD was analyzed using recorded EEG data, and all data analysis was done by blind method. SWD was analyzed in 20 minutes of baseline phase and in a period of 10 minutes to 90 minutes after drug administration for a total of 80 minutes. 80 minutes were analyzed in 20 minute intervals, and the number of SWD occurrences and cumulated SWD duration (SWD cumulative duration) were analyzed.
- Results were expressed as means ⁇ standard error, and statistical analysis was done using prism (graph pads).
- Two-way ANOVA was used for the number of SWD occurrences and cumulative duration of SWD over time. Bonferroni's paired (paired) test was used for comparison with baseline, vehicle-negative control, and valproate- comparison method. The 1-way ANOVA was used for repeated measures for the total effect for 1 hour after the drug administration, compared with vehicle-negative control, Bonferroni's paired comparison method. The criterion for statistical significance was defined as p ⁇ 0.05.
- the negative control group did not show any difference from baseline at any time.
- the frequency of SWD was significantly decreased compared with vehicle.
- 10 mg / kg dose 30 to 50 minutes after administration, 30 to 90 minutes at 20 mg / kg dose, and 30 mg / kg dose at all doses.
- the duration of the treatment was longer than that of the positive control group valproate.
- the negative control group did not show any difference from baseline at any time.
- valproate In the positive control group valproate, there was a decrease in cumulative persistence of SWD by valproate administration. At 150 mg / kg administration, there was a significant decrease at 10-30, 30-50 and 50-70 minutes after administration, and the total time interval (10-90 minutes) after administration at 200 mg / There was a significant decrease from the negative control group.
- the cumulative duration of SWD was significantly lower than that of vehicle.
- the duration of the treatment was longer than that of the positive control group valproate.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (36)
- 제1항에 있어서, R1 및 R2가 각각 독립적으로 수소, 할로겐 및 C1-C8 알킬로 이루어진 그룹으로부터 선택되는 것을 특징으로 하는 약제.
- 제1항에 있어서, 결신발작 또는 결신발작을 나타내는 뇌전증을 앓고 있는 개체가 SWD(spike-and-wave discharges) 뇌파를 나타내는 것을 특징으로 하는 약제.
- 제1항에 있어서, 결신발작을 나타내는 뇌전증이 소아 결신발작 뇌전증 (child absence epilepsy), 근간대성 결신발작 뇌전증(epilepsy with myoclonic absence), 청소년기 결신발작 뇌전증(juvenile absence epilepsy), 청소년기 근육간대경련 뇌전증(juvenile myoclonic epilepsy), Jeavons 증후군(결신발작을 동반한 눈꺼풀 근육간대경련, eyelid myoclonia with absences), 환상 결신발작을 동반한 유전성 일반 뇌전증(genetic generalised epilepsy with phantom absences), 및 레녹스 가스토 증후군(Lennox-Gastaut syndrome)으로 구성된 그룹 중에서 선택되는 것을 특징으로 하는 약제.
- 제1항에 있어서, 결신발작이 정형결신(typical absence)발작인 것을 특징으로 하는 약제.
- 제1항에 있어서, 결신발작이 비정형결신(atypical absence)발작인 것을 특징으로 하는 약제.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 포유 동물 투여용인 것을 특징으로 하는 약제.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 화학식 1의 카바메이트 화합물의 치료학적 유효량이 1일 1회 투여시 유리형 기준으로 50 내지 500 mg인 것을 특징으로 하는 약제.
- 제10항에 있어서, R1 및 R2가 각각 독립적으로 수소, 할로겐 및 C1-C8 알킬로 이루어진 그룹으로부터 선택되는 것을 특징으로 하는 약제학적 조성물.
- 제10항에 있어서, 결신발작 또는 결신발작을 나타내는 뇌전증을 앓고 있는 개체가 SWD(spike-and-wave discharges) 뇌파를 나타내는 것을 특징으로 하는 약제학적 조성물.
- 제10항에 있어서, 결신발작을 나타내는 뇌전증이 소아 결신발작 뇌전증 (child absence epilepsy), 근간대성 결신발작 뇌전증(epilepsy with myoclonic absence), 청소년기 결신발작 뇌전증(juvenile absence epilepsy), 청소년기 근육간대경련 뇌전증(juvenile myoclonic epilepsy), Jeavons 증후군(결신발작을 동반한 눈꺼풀 근육간대경련, eyelid myoclonia with absences), 환상 결신발작을 동반한 유전성 일반 뇌전증(genetic generalised epilepsy with phantom absences), 및 레녹스 가스토 증후군(Lennox-Gastaut syndrome)으로 구성된 그룹 중에서 선택되는 것을 특징으로 하는 약제학적 조성물.
- 제10항에 있어서, 결신발작이 정형결신(typical absence)발작인 것을 특징으로 하는 약제학적 조성물.
- 제10항에 있어서, 결신발작이 비정형결신(atypical absence)발작인 것을 특징으로 하는 약제학적 조성물.
- 제10항 내지 제16항 중 어느 한 항에 있어서, 포유 동물 투여용인 것을 특징으로 하는 약제학적 조성물.
- 제10항 내지 제16항 중 어느 한 항에 있어서, 화학식 1의 카바메이트 화합물의 치료학적 유효량이 1일 1회 투여시 유리형 기준으로 50 내지 500 mg인 것을 특징으로 하는 약제학적 조성물.
- 제19항에 있어서, R1 및 R2가 각각 독립적으로 수소, 할로겐 및 C1-C8 알킬로 이루어진 그룹으로부터 선택되는 것을 특징으로 하는 용도.
- 제19항에 있어서, 결신발작 또는 결신발작을 나타내는 뇌전증을 앓고 있는 개체가 SWD(spike-and-wave discharges) 뇌파를 나타내는 것을 특징으로 하는 용도.
- 제19항에 있어서, 결신발작을 나타내는 뇌전증이 소아 결신발작 뇌전증 (child absence epilepsy), 근간대성 결신발작 뇌전증(epilepsy with myoclonic absence), 청소년기 결신발작 뇌전증(juvenile absence epilepsy), 청소년기 근육간대경련 뇌전증(juvenile myoclonic epilepsy), Jeavons 증후군(결신발작을 동반한 눈꺼풀 근육간대경련, eyelid myoclonia with absences), 환상 결신발작을 동반한 유전성 일반 뇌전증(genetic generalised epilepsy with phantom absences), 및 레녹스 가스토 증후군(Lennox-Gastaut syndrome)으로 구성된 그룹 중에서 선택되는 것을 특징으로 하는 용도.
- 제19항에 있어서, 결신발작이 정형결신(typical absence)발작인 것을 특징으로 하는 용도.
- 제19항에 있어서, 결신발작이 비정형결신(atypical absence)발작인 것을 특징으로 하는 용도.
- 제19항 내지 제25항 중 어느 한 항에 있어서, 약제가 포유 동물 투여용인 것을 특징으로 하는 용도.
- 제19항 내지 제25항 중 어느 한 항에 있어서, 화학식 1의 카바메이트 화합물의 치료학적 유효량이 1일 1회 투여시 유리형 기준으로 50 내지 500 mg인 것을 특징으로 하는 용도.
- 치료학적 유효량의 하기 화학식 1의 카바메이트 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물을, 이를 필요로 하는 대상에 투여하는 것을 포함하는, 결신발작(absence seizure) 또는 결신발작을 나타내는 뇌전증(epilepsy)의 예방, 경감 또는 치료 방법:[화학식 1]상기 화학식 1에서,R1 및 R2는 각각 독립적으로 수소, 할로겐, C1-C8 알킬, 할로 C1-C8 알킬, C1-C8 티오알콕시 및 C1-C8 알콕시로 이루어진 그룹으로부터 선택되고,A1 및 A2에서 어느 하나는 CH이며, 다른 하나는 N이다.
- 제28항에 있어서, R1 및 R2가 각각 독립적으로 수소, 할로겐 및 C1-C8 알킬로 이루어진 그룹으로부터 선택되는 것을 특징으로 하는 방법.
- 제28항에 있어서, 결신발작 또는 결신발작을 나타내는 뇌전증을 앓고 있는 개체가 SWD(spike-and-wave discharges) 뇌파를 나타내는 것을 특징으로 하는 방법.
- 제28항에 있어서, 결신발작을 나타내는 뇌전증이 소아 결신발작 뇌전증 (child absence epilepsy), 근간대성 결신발작 뇌전증(epilepsy with myoclonic absence), 청소년기 결신발작 뇌전증(juvenile absence epilepsy), 청소년기 근육간대경련 뇌전증(juvenile myoclonic epilepsy), Jeavons 증후군(결신발작을 동반한 눈꺼풀 근육간대경련, eyelid myoclonia with absences), 환상 결신발작을 동반한 유전성 일반 뇌전증(genetic generalised epilepsy with phantom absences), 및 레녹스 가스토 증후군(Lennox-Gastaut syndrome)으로 구성된 그룹 중에서 선택되는 것을 특징으로 하는 방법.
- 제28항에 있어서, 결신발작이 정형결신(typical absence)발작인 것을 특징으로 하는 방법.
- 제28항에 있어서, 결신발작이 비정형결신(atypical absence)발작인 것을 특징으로 하는 방법.
- 제28항에 있어서, 투여 대상이 포유동물인 것을 특징으로 하는 방법.
- 제28항에 있어서, 화학식 1의 카바메이트 화합물의 치료학적 유효량이 1일 1회 투여시 유리형 기준으로 50 내지 500 mg인 것을 특징으로 하는 방법.
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020544727A JP7258901B2 (ja) | 2017-11-14 | 2018-11-13 | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
MX2020004972A MX2020004972A (es) | 2017-11-14 | 2018-11-13 | Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia. |
KR1020207013843A KR20200074153A (ko) | 2017-11-14 | 2018-11-13 | 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
BR112020009265-7A BR112020009265A2 (pt) | 2017-11-14 | 2018-11-13 | medicamento e composição farmacêutica para a prevenção, alívio ou tratamento de crise de ausência ou epilepsia que apresenta crise de ausência, uso de um composto de carbamato ou um sal, solvato ou hidrato do mesmo, e, método para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência. |
CA3081223A CA3081223A1 (en) | 2017-11-14 | 2018-11-13 | Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure |
FIEP18878222.1T FI3711758T3 (fi) | 2017-11-14 | 2018-11-13 | Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi |
EP18878222.1A EP3711758B1 (en) | 2017-11-14 | 2018-11-13 | Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure |
AU2018367729A AU2018367729A1 (en) | 2017-11-14 | 2018-11-13 | Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure |
RU2020119292A RU2787771C2 (ru) | 2017-11-14 | 2018-11-13 | Применение карбаматного производного для предотвращения, облегчения или лечения малого эпилептического припадка или эпилепсии, проявляющей малый эпилептический припадок |
DK18878222.1T DK3711758T3 (da) | 2017-11-14 | 2018-11-13 | Anvendelse af en carbamatforbindelse til forebyggelse, lindring eller behandling af fraværsanfald eller epilepsi med fraværsanfald |
US16/763,636 US20200352907A1 (en) | 2017-11-14 | 2018-11-13 | Use Of Carbamate Compound For Preventing, Alleviating Or Treating Absence Seizure Or Epilepsy Showing Absence Seizure |
CN201880073833.7A CN111432812A (zh) | 2017-11-14 | 2018-11-13 | 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途 |
IL274428A IL274428B2 (en) | 2017-11-14 | 2020-05-04 | Use of a carbamate compound to prevent, relieve or treat a withdrawal seizure or epilepsy presenting with a withdrawal seizure |
JP2023061633A JP2023085469A (ja) | 2017-11-14 | 2023-04-05 | 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0151248 | 2017-11-14 | ||
KR20170151248 | 2017-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019098628A1 true WO2019098628A1 (ko) | 2019-05-23 |
Family
ID=66540315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/013761 WO2019098628A1 (ko) | 2017-11-14 | 2018-11-13 | 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200352907A1 (ko) |
EP (1) | EP3711758B1 (ko) |
JP (2) | JP7258901B2 (ko) |
KR (1) | KR20200074153A (ko) |
CN (1) | CN111432812A (ko) |
AU (1) | AU2018367729A1 (ko) |
BR (1) | BR112020009265A2 (ko) |
CA (1) | CA3081223A1 (ko) |
DK (1) | DK3711758T3 (ko) |
FI (1) | FI3711758T3 (ko) |
IL (1) | IL274428B2 (ko) |
MX (1) | MX2020004972A (ko) |
PT (1) | PT3711758T (ko) |
WO (1) | WO2019098628A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3113052A1 (en) * | 2018-09-21 | 2020-03-26 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006112685A1 (en) | 2005-04-22 | 2006-10-26 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
WO2010150946A1 (en) | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
WO2011046380A2 (en) | 2009-10-15 | 2011-04-21 | Sk Holdings Co.,Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1707204A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands |
-
2018
- 2018-11-13 CA CA3081223A patent/CA3081223A1/en active Pending
- 2018-11-13 US US16/763,636 patent/US20200352907A1/en active Pending
- 2018-11-13 CN CN201880073833.7A patent/CN111432812A/zh active Pending
- 2018-11-13 EP EP18878222.1A patent/EP3711758B1/en active Active
- 2018-11-13 AU AU2018367729A patent/AU2018367729A1/en active Pending
- 2018-11-13 PT PT188782221T patent/PT3711758T/pt unknown
- 2018-11-13 BR BR112020009265-7A patent/BR112020009265A2/pt unknown
- 2018-11-13 JP JP2020544727A patent/JP7258901B2/ja active Active
- 2018-11-13 FI FIEP18878222.1T patent/FI3711758T3/fi active
- 2018-11-13 MX MX2020004972A patent/MX2020004972A/es unknown
- 2018-11-13 KR KR1020207013843A patent/KR20200074153A/ko active Search and Examination
- 2018-11-13 WO PCT/KR2018/013761 patent/WO2019098628A1/ko unknown
- 2018-11-13 DK DK18878222.1T patent/DK3711758T3/da active
-
2020
- 2020-05-04 IL IL274428A patent/IL274428B2/en unknown
-
2023
- 2023-04-05 JP JP2023061633A patent/JP2023085469A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006112685A1 (en) | 2005-04-22 | 2006-10-26 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
KR20080005437A (ko) * | 2005-04-22 | 2008-01-11 | 에스케이 주식회사 | 신경치료용 아졸 화합물 |
WO2010150946A1 (en) | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
KR20100137389A (ko) * | 2009-06-22 | 2010-12-30 | 에스케이 주식회사 | 카르밤산 (r)-1-아릴-2-테트라조릴-에틸 에스테르의 제조 방법 |
WO2011046380A2 (en) | 2009-10-15 | 2011-04-21 | Sk Holdings Co.,Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
KR20120087124A (ko) * | 2009-10-15 | 2012-08-06 | 에스케이바이오팜 주식회사 | 카르밤산 (r)-1-아릴-2-테트라졸릴-에틸 에스테르의 제조 방법 |
Non-Patent Citations (12)
Title |
---|
BIALER, M. ET AL.: "Progress Report on new Antiepileptic Drugs: A Summary of the Twelfth Eilat Conference (EILAT XII", EPILEPSY RESEARCH, vol. 1, no. 11, 2015, pages 85 - 141, XP055608941 * |
DEDEURWAERDERE ET AL.: "Fluctuating and constant valproate administration gives equivalent seizure control in rats with genetic and acquired epilepsy", SEIZURE, vol. 20, no. 1, January 2011 (2011-01-01), pages 72 - 9, XP027570829 |
DEPAULIS ET AL.: "The genetic absence epilepsy rat from Strasbourg as a model to decipher the neuronal and network mechanisms of generalized idiopathic epilepsies", J NEUROSCI METHODS, vol. 260, 15 February 2016 (2016-02-15), pages 159 - 74, XP029405999, DOI: 10.1016/j.jneumeth.2015.05.022 |
GLAUSER ET AL.: "Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy", NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 9, 2010, pages 790 - 9 |
GOLYALA, A. ET AL.: "Drug Development for Refractory Epilepsy: The Past 25 Years and Beyond", SEIZURE, vol. 44, January 2017 (2017-01-01), pages 147 - 156, XP029901803, DOI: doi:10.1016/j.seizure.2016.11.022 * |
GURBANOVA ET AL.: "Effect of systemic and intracortical administration of phenytoin in two genetic models of absence epilepsy", BR J PHARMACOL., vol. 148, no. 8, August 2006 (2006-08-01), pages 1076 - 82 |
KLITGAARD ET AL.: "Use of epileptic animals for adverse effect testing", EPILEPSY RES., vol. 50, no. 1-2, June 2002 (2002-06-01), pages 55 - 65 |
KNAKE ET AL.: "Tiagabine-induced absence status in idiopathic generalized epilepsy", EUROPEAN JOURNAL OF EPILEPSY, vol. 8, no. 5, 8 August 1999 (1999-08-08), pages 314 - 317 |
NEHLIG ET AL.: "Cerebral energy metabolism in rats with genetic absence epilepsy is not correlated with the pharmacological increase or suppression of spike-wave discharges", BRAIN RES., vol. 618, no. 1, 30 July 1993 (1993-07-30), pages 1 - 8, XP024282154, DOI: 10.1016/0006-8993(93)90421-I |
VAN LUIJTELAAR ELDRINKENBURG WHVAN RIJN CMCOENEN AM: "Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects?", METHODS FIND EXP CLIN PHARMACOL., vol. 24, no. D, 2002, pages 65 - 70 |
VARTANIAN ET AL.: "Activity profile of pregabalin in rodent models of epilepsy and ataxia", EPILEPSY RES., vol. 68, no. 3, March 2006 (2006-03-01), pages 189 - 205, XP025114989, DOI: 10.1016/j.eplepsyres.2005.11.001 |
WALLENGREN ET AL.: "Aggravation of absence seizures by carbamazepine in a genetic rat model does not induce neuronal c-Fos activation", CLIN NEUROPHARMACOL., vol. 28, no. 2, March 2005 (2005-03-01), pages 60 - 5 |
Also Published As
Publication number | Publication date |
---|---|
EP3711758A4 (en) | 2021-08-04 |
KR20200074153A (ko) | 2020-06-24 |
FI3711758T3 (fi) | 2024-05-13 |
RU2020119292A3 (ko) | 2022-02-24 |
DK3711758T3 (da) | 2024-04-08 |
BR112020009265A2 (pt) | 2020-10-20 |
PT3711758T (pt) | 2024-04-22 |
JP2023085469A (ja) | 2023-06-20 |
EP3711758A1 (en) | 2020-09-23 |
MX2020004972A (es) | 2020-08-24 |
JP2021503010A (ja) | 2021-02-04 |
US20200352907A1 (en) | 2020-11-12 |
CA3081223A1 (en) | 2019-05-23 |
IL274428A (en) | 2020-06-30 |
IL274428B2 (en) | 2023-08-01 |
EP3711758B1 (en) | 2024-03-27 |
JP7258901B2 (ja) | 2023-04-17 |
CN111432812A (zh) | 2020-07-17 |
AU2018367729A1 (en) | 2020-05-21 |
RU2020119292A (ru) | 2021-12-15 |
IL274428B1 (en) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017200318A1 (ko) | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 | |
EP1872795A1 (en) | Therapeutic agent for irritable bowel syndrome | |
WO2019098628A1 (ko) | 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
KR102421006B1 (ko) | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 | |
WO2018111008A1 (ko) | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
WO2017200317A1 (ko) | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 | |
WO2018111009A1 (ko) | 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
WO2020060252A1 (ko) | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 | |
WO2021215798A1 (ko) | 사스 코로나바이러스 감염증 치료용 약학 조성물 및 이의 의약 용도 | |
RU2787771C2 (ru) | Применение карбаматного производного для предотвращения, облегчения или лечения малого эпилептического припадка или эпилепсии, проявляющей малый эпилептический припадок | |
CN111432814B (zh) | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 | |
WO2018111003A1 (ko) | 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
KR20190054559A (ko) | 염증성 통증 또는 염증성 질환에서 기인한 통증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
WO2020060251A1 (ko) | 카바메이트 화합물 및 이를 포함하는 배합물의 급성 스트레스 장애 또는 외상 후 스트레스 장애의 예방, 경감 또는 치료를 위한 용도 | |
RU2793742C2 (ru) | Применение карбаматного соединения для снижения или лечения нарушений развития, включая синдром хрупкой x-хромосомы, синдром ангельмана или синдром ретта | |
WO2020009403A1 (ko) | 수면 장애의 예방 또는 치료용 약학적 조성물 | |
WO2020196694A1 (ja) | 嗅覚障害及び神経変性疾患の治療及び/又は予防剤 | |
RU2776368C2 (ru) | Применение карбаматного соединения для профилактики, облегчения или лечения треморов или синдрома тремора | |
WO2019098632A1 (ko) | 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
CN112402408A (zh) | 盐酸丙美卡因及其衍生化合物在制备预防和/或治疗癫痫药物中的应用 | |
JP4615849B2 (ja) | プロパフェノン含有神経因性疼痛の鎮痛剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18878222 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3081223 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020544727 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20207013843 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018367729 Country of ref document: AU Date of ref document: 20181113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018878222 Country of ref document: EP Effective date: 20200615 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020009265 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020009265 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200511 |